How ATR kinase inhibitors affect immune cell growth and memory in cancer treatment
The Impact of ATR Kinase Inhibitors on CD8+ T Cell Expansion and Memory Development
This study is looking at how certain drugs can help boost the immune system's ability to fight cancer by working with radiation therapy, and it's being tested in mice to see if it can make immune cells stronger and more effective against tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11061551 on NIH RePORTER |
What this research studies
This research investigates the role of ATR kinase inhibitors in enhancing the immune response of CD8+ T cells, which are crucial for fighting cancer. By using these inhibitors alongside radiation therapy, the study aims to improve the effectiveness of cancer treatments by promoting the expansion and memory development of these immune cells. The researchers will utilize a unique mouse model to explore how these inhibitors can alter DNA replication and transcription in immune cells, potentially leading to better anti-tumor responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing radiation therapy for cancer who may benefit from enhanced immune responses.
Not a fit: Patients who are not receiving radiation therapy or those with conditions unrelated to cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by harnessing the body's immune system to better target and eliminate cancer cells.
How similar studies have performed: Previous research has shown promise in using DNA damage response inhibitors to enhance immune responses, suggesting that this approach could be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Bakkenist, Christopher J. — University of Pittsburgh at Pittsburgh
- Study coordinator: Bakkenist, Christopher J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.